Immunosuppressants - South America

South America

The Immunosuppressants market in South America is projected to achieve a revenue of US$1.08bn by the year 2024.
It is expected to demonstrate a compound annual growth rate (CAGR 2024-2029) of 15.29%, ultimately leading to a market volume of US$2.20bn by 2029.
Comparatively, United States will generate the highest revenue of US$35,470.00m in 2024.
The demand for immunosuppressants in South America has been steadily increasing, driven by a rise in organ transplantation and autoimmune diseases.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The market for immunosuppressants in South America is a rapidly growing industry, with increasing demand for these drugs in the region.

Customer preferences: The customer preferences for immunosuppressants in South America are largely driven by the rising incidence of autoimmune diseases and organ transplantation in the region. Patients with autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and lupus require immunosuppressants to manage their conditions. Similarly, organ transplant recipients require these drugs to prevent rejection of the transplanted organ.

Trends in the market: One of the major trends in the immunosuppressants market in South America is the increasing availability of generic versions of these drugs. This has led to a decrease in prices, making these drugs more affordable for patients. Another trend is the increasing use of biologic drugs, which are more effective than traditional immunosuppressants and have fewer side effects.

Local special circumstances: One of the unique circumstances in South America is the high prevalence of certain autoimmune diseases such as rheumatoid arthritis and lupus. This has led to a higher demand for immunosuppressants in the region. Additionally, the region has a high incidence of organ transplantation, which also drives demand for these drugs.

Underlying macroeconomic factors: The underlying macroeconomic factors driving the growth of the immunosuppressants market in South America include the increasing prevalence of autoimmune diseases and organ transplantation in the region. Additionally, the rising healthcare expenditure in the region is driving demand for these drugs. However, the market is also facing challenges such as the high cost of biologic drugs and the lack of availability of certain immunosuppressants in some countries.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.